Advising Carbosynth on merger with Biosynth

We have advised Carbosynth, a worldwide supplier of carbohydrates, nucleosides and biochemicals, on its merger with Biosynth AG of Switzerland.

Both companies have diverse expertise in organic synthesis and different focuses in their portfolio of bio-chemicals. Carbosynth is a well-established leader in carbohydrate chemistry, whilst Biosynth has a wealth of experience with enzyme substrates. The merger will create a leading player in the global fine chemicals market.

Corporate partner, Andrew Peddie led the deal and acted for the shareholders at Carbosynth. He was supported by Corporate solicitor, Laurel Knight, and the wider team of specialists including David Williams and Jim Hillan in Tax, Colin Gittus and Marissa Carey in Property and Mailin Bala in Commercial. Squires Patton Boggs (Corporate Partner Darren Warburton, Corporate Associate Matt Canipa) advised Biosynth.

Dr. Vanessa Eastwick-Field, managing director for Carbosynth, said: “We are delighted to join forces and pool resources with Biosynth, who we have known and worked with for many years. They have a proven track record of looking after customers and an extensive line of biomedical products to match their expertise in manufacturing and GMP. This new partnership will enhance the relationship we have with our customers, create a more streamlined and comprehensive product range and allow for even better customer service”.

Andrew Peddie at Gateley Plc added: “It was great to work with the Carbosynth team, and with James Cowper Kreston LLP their Corporate Finance and Tax advisers, on this matter. Carbosynth was founded by Vanessa and her colleagues only a dozen or so years ago but over that time they have clearly built a very valuable business both in the UK and internationally, and the fit with Biosynth seems ideal.

“I am sure that between them they will take the business on to even greater success over the coming years.”